Clinical Trial Update: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating NGR-hTNF in combination with doxorubicin for platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED